Vanderbilt Researchers’ Potential Alzheimer’s Therapy Being Tested in Phase 1 Study

Vanderbilt Researchers’ Potential Alzheimer’s Therapy Being Tested in Phase 1 Study
Vanderbilt University researchers have developed a potential therapy for Alzheimer’s disease (AD) that has shown promising results in brain health. The investigative treatment, a molecule called VU319, is expected to fill a long-needed gap for Alzheimer’s patients by improving memory, attention, and brain functioning. The U.S. Food and Drug Administration (FDA) has cleared the drug to move into human clinical trials to determine the proper dose and safety profile. VU319 is currently being tested in healthy human volunteers. The first patient was dosed on July 29 in a first-in-human Phase 1 clinical trial at the Vanderbilt Institute for Clinical and Translational Research. If
Subscribe or to access all post and page content.

One comment

  1. Linda Grishman says:

    How are these people getting into clinical trials? My doctor is useless so I have found my own sources. Albany Med Center has some promising results with a new drug. I will be going to Albany in the next few werks. I pray that it will clear the plaque and I will be back to my normal self. As you can see, I am still fully cognicent and that is a plus.

    Best,
    Linda Grishman.
    Burlington, VT

Leave a Comment

Your email address will not be published. Required fields are marked *